PARP Inhibitors in Oncology | A Drug Pipeline Analysis Report 2018 | Technavio

Technavio has published a new report on the drug development pipeline for PARP inhibitors in oncology, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the PARP inhibitors in oncology. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period for PARP inhibitors in oncology.

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

PARP inhibitors: Market overview

Poly-ADP ribose polymerase (PARP) inhibitor is a targeted class of cancer drugs. PARP is a protein present in cells of the human body, which helps the damaged cells to repair themselves by playing a role in various DNA repair pathways. PARP inhibitors inhibit the repair of DNA damage in the cell and thus result in the accumulation of deleterious mutations leading to genetic instability.

According to a senior market research analyst at Technavio, “The PARP inhibitors are undergoing development for the treatment of various cancer types such as breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, lung cancer, and gastric cancer. According to the Center for Disease Control and Prevention report, the national expenditure for the care of cancer in the US, in 2017, was USD 147 billion, which is expected to rise further due to the high cost of new drugs and adoption of advanced treatment options as standards of care.”

PARP inhibitors in oncology: Segmentation analysis

This pipeline analysis report segments the PARP inhibitors in oncology market based on therapies employed (monotherapy, monotherapy/ combination therapy, and combination therapy), RoA (oral and inhalational), therapeutic modality (small molecule), geographical segmentation (Asia, Americas and EMEA) and recruitment status (active, but not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on the route of administration, 85% of the molecules that are being investigated for PARP inhibitors in oncology are oral drugs.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

Technavio has published a new report on the drug development pipeline for PARP inhibitors in oncology, including a study of the pipeline molecules.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200